Biogen Inc. buy The Goldman Sachs Group, Inc.
Start price
13.02.25
/
50%
€132.80
Target price
13.02.26
€234.78
Performance (%)
11.41%
Price
22.01.26
€147.95
Summary
This prediction is currently active. The prediction currently has a performance of 11.41%. This prediction currently runs until 13.02.26. The prediction end date can be changed by The_Goldman_Sachs_Gr at any time. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Biogen Inc. | 1.824% | 1.824% |
| iShares Core DAX® | -1.673% | 2.237% |
| iShares Nasdaq 100 | -1.346% | 0.290% |
| iShares Nikkei 225® | -1.529% | 5.863% |
| iShares S&P 500 | -1.702% | 0.697% |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Biogen Inc. diskutieren
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $281.00 to $245.00. They now have a "buy" rating on the stock.
Ratings data for BIIB provided by MarketBeat